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1. INTRODUCTION {#clc23230-sec-0001}
===============

In 2007, the Global Myocardial Infarction (MI) Task Force released an expert consensus document classifying MI into five different subtypes.[1](#clc23230-bib-0001){ref-type="ref"} In 2012, the third universal definition of myocardial infarction provided a new classification of MI, which was based on etiology.[2](#clc23230-bib-0002){ref-type="ref"} In 2018, the fourth universal definition of MI brought forward a detailed classification of MI. Type 2 myocardial infarction (T2MI) is defined as MI not caused by plaque rupture, ulceration, erosion, or dissection with thrombotic obstruction, but secondary to myocardial oxygen supply‐demand imbalance related to an underlying cause. The definition of T2MI contains three aspects: (a) detection of a rise and/or fall in cardiac troponin (cTn) values with at least one value above the 99th percentile upper reference limit (URL); (b) clinical presentation of acute myocardial ischemia; and (c) evidence of an imbalance between myocardial oxygen supply and demand.[3](#clc23230-bib-0003){ref-type="ref"} T2MI may be multifactorial and caused by various conditions, such as anemia, arrhythmia, sepsis, infection, heart failure, respiratory failure, coronary artery spasm, hypertension, hypotension, aortic dissection, severe aortic valve disease, hypertrophic cardiomyopathy, or postoperative factors, but no specific criteria for the diagnosis of T2MI have been established.[4](#clc23230-bib-0004){ref-type="ref"} The lack of objective criteria for T2MI creates a diagnostic uncertainty, which has led to the inconsistent adoption of the classification in clinical practice. Thus far, the classification of T2MI is contentious because of the underlying pathological mechanisms and is based on expert consensus rather than evidence from prospective randomized controlled clinical trials. Patients diagnosed with T2MI are heterogeneous and have myocardial ischemia secondary to a variety of acute medical or surgical conditions.

Notably, little is still known about the correlation between triggering factors, clinical characteristics, diagnosis, and prognosis of patients with T2MI. Based on the current criteria, a diagnosis of T2MI could be applied to patients without atherosclerotic plaque disruption.[5](#clc23230-bib-0005){ref-type="ref"} Although patients with T2MI have higher rates of all‐cause death compared with those with type 1 myocardial infarction (T1MI), few studies report that the causes of T2MI are associated with a higher mortality rate. In addition, distinguishing different etiologies is essential for clinical management in patients with T2MI, mainly because a large spectrum of underlying causes for T2MI leads to an array of different treatment strategies.[6](#clc23230-bib-0006){ref-type="ref"}, [7](#clc23230-bib-0007){ref-type="ref"}, [8](#clc23230-bib-0008){ref-type="ref"}, [9](#clc23230-bib-0009){ref-type="ref"} Hence, the aim of this review is to assess the triggers of T2MI and to summarize the clinical features of patients with T2MI described in the literature.

2. METHODS {#clc23230-sec-0002}
==========

There is currently no consensus on the correct tool or measurement parameters to define T2MI, with different troponin I and T value ranges identifying T2MI currently in use. Moreover, there is no universal consensus on the cTn cut‐off points that clearly distinguish T2MI from MI. We therefore elected to include papers that had used any of the most commonly accepted metrics, according to a rise and/or fall in cTn values with at least one value above the 99th percentile URL.[3](#clc23230-bib-0003){ref-type="ref"}

We followed the Preferred Reporting Items for Systematic Reviews and Meta‐Analysis (PRISMA) guidelines for this systematic review.[10](#clc23230-bib-0010){ref-type="ref"} The objective of this review was to identify all articles published in PubMed, Embase, and Medline databases between January 2012 and August 2018, which assessed the triggers of T2MI. Multiple variations of the following terms were utilized: cause, contributing factor, trigger, alternate factor, instigating factor, type 2 myocardial infarction, type II myocardial infarction, and myocardial infarction type 2. Additional references were identified from conference proceedings and/or citations in relevant review articles and assessed to find all available papers.

The inclusion criteria were as follows: (a) the definition, different causes, and baseline features of T2MI were mentioned; (b) an available clinical database was used; and (c) the study design met the requirement of high or acceptable quality assessment; especially, the single‐ and multiple‐trigger T2MI should be both included in selected studies. The exclusion criteria were as follows: (a) duplicate reporting; (b) lack of outcome data; and (c) non‐English publication.

Two investigators (G.Q.W. and N.Z.) independently evaluated the titles and abstracts of the articles retrieved using the search strategy. Abstracts that did not meet the inclusion criteria or met exclusion criteria were discarded. We selected the remaining studies for full‐text evaluation and data extraction. Any disagreements regarding the inclusion or exclusion of a study were solved by consensus, and, if doubt persisted, a third reviewer (J.P.L.) evaluated the reference. Therefore, we extracted data on the different causes of T2MI, which contained arrhythmia, anemia, respiratory failure, hypotension, infection and sepsis, heart failure, hypertension, postoperative factors, and other factors. Additionally, the data of multi‐trigger T2MI was extracted from selected studies.

3. RESULTS {#clc23230-sec-0003}
==========

Our literature search identified 7386 articles corresponding to the key terms; 7306 were excluded because they were not relevant based on the title and abstract. The full text of 80 articles was evaluated and 14 articles were ultimately included in this review. After screening the reference list of all included articles, no articles were added to this review. A detailed description of the selection process is presented in Figure [1](#clc23230-fig-0001){ref-type="fig"}. The 14 selected articles included 7 retrospective cohort studies and 7 prospective cohort studies involving 3867 patients with T2MI. The clinical characteristics of selected patients are shown in Table [1](#clc23230-tbl-0001){ref-type="table"}.

![Flow diagram of the study selection process](CLC-42-1019-g001){#clc23230-fig-0001}

###### 

Baseline characteristics and treatment of patients with T2MI

  Characteristics                                      EI‐Haddad H 2012                                     Saaby L 2013   Baron T 2014   Saaby L 2014   Stein GY 2014   Szymariski FM 2014   Sandoval Y 2015   Lopez‐Cuenca A 2016   Landes U 2016   Smilowitz NR 2017   Radovanovic D 2017   Sandoval Y 2017   Nestelberger T 2017                                Arora S 2018
  ---------------------------------------------------- ---------------------------------------------------- -------------- -------------- -------------- --------------- -------------------- ----------------- --------------------- --------------- ------------------- -------------------- ----------------- -------------------------------------------------- --------------------------------------------------
  Demographic/physical findings                                                                                                                                                                                                                                                                                                                                     
  Age ±mean (SD)                                       67.2(21‐99)[b](#clc23230-note-0004){ref-type="fn"}   75±11          75.9±11.4      75±11          75±12           67.3 ± 13.2          61±8              72±12                 74±10.4         74.3±12.2           70.8±13.3            60±15             72(58‐81)[b](#clc23230-note-0004){ref-type="fn"}   73(64‐81)[b](#clc23230-note-0004){ref-type="fn"}
  Female sex (%)                                       126(42.7)                                            68(47.2)       657(46.8)      56(47.1)       55(43.4)        35(60.3)             13(59.0)          56(47.9)              38(35.5)        2(1.4)              387(35.5)            60(43)            92(38.3)                                           137(51.9)
  Body mass index \[kg/m^2^\]±mean (SD)                NA                                                   NA             NA             NA             25.8±4          27.56 ± 4.48         NA                NA                    NA              NA                  NA                   29±8              26±2                                               26(23‐31)[b](#clc23230-note-0004){ref-type="fn"}
  Systolic BP \[mm Hg\]±mean (SD)                      NA                                                   139±30.5       140.4±31.2     139±28.5       143±33          135.64 ± 23.17       142.5±18.5        135 ± 31              NA              NA                  136±29               154±39            NA                                                 NA
  Diastolic BP \[mm Hg\]±mean (SD)                     NA                                                   77±17          79.3±18.0      NA             79±19           78.11±13.54          NA                72 ± 17               NA              NA                  77±18                92±27             NA                                                 NA
  Heart rate \[bpm\]±mean (SD)                         NA                                                   113±20.5       97.8±30.5      112±20         95±25           81.39 ± 23.63        115.5±12.5        102 ± 36              NA              NA                  84±25                100±30            NA                                                 NA
  NSTEMI(%)                                            NA                                                   139(96.6)      1267(90.3)     115(96.6)      89(70.1)        42(72.4)             NA                116(99.1)             96(89.7)        NA                  878(80.5)            109(77.9)         234(97.5)                                          NA
  Medical history                                                                                                                                                                                                                                                                                                                                                   
  Hypertension(%)                                      NA                                                   81(56.3)       760(54.2)      66(55.5)       108(84.9)       42(72.4)             14(64)            103(88)               87(81.3)        128(87.7)           766(73.5)            104(74.3)         182(75.8)                                          225(86)
  Coronary artery disease (%)                          NA                                                   NA             NA             NA             50(39.7)        NA                   NA                59(50.4)              68 (63.6)       NA                  392(36.8)            24(17.1)          86(77.0)                                           NA
  Previous myocardial infarction(%)                    NA                                                   39(27.1)       563(40.1)      26(21.9)       56(44.4)        15(25.9)             3(14)             19(16.2)              NA              28(19.2)            NA                   15(10.7)          58(24.2)                                           NA
  Previous coronary artery bypass surgery(%)           NA                                                   14(9.7)        206(14.7)      9(7.6)         18(14.2)        NA                   1(5)              12(10.3)              NA              27(18.5)            NA                   NA                NA                                                 51(19)
  Previous percutaneous coronary intervention(%)       NA                                                   25(17.4)       244(17.4)      15(12.6)       47(37.1)        NA                   3(14)             40(34.2)              49 (46.2)       25(17.1)            NA                   NA                64(26.7)                                           56(21)
  Diabetes(%)                                          NA                                                   40(27.9)       376(26.8)      28(23.5)       61(48)          14(24.1)             9(41)             52(44.4)              54(50.5)        58(39.7)            276(26.2)            43(30.7)          209(87.1)                                          110(42)
  Dyslipidaemia(%)                                     NA                                                   60(41.8)       NA             48(40.3)       93(73.2)        23(39.7)             9(41)             89(76.1)              82 (76.6)       102(69.9)           565(57.8)            61(43.6)          124(51.7)                                          131(50)
  Obesity (BMI\> 30) (%)                               NA                                                   NA             NA             NA             NA              NA                   NA                NA                    NA              NA                  213(22.6)            NA                NA                                                 NA
  Cerebrovascular disease(%)                           NA                                                   31(21.5)       195(13.9)      24(20.2)       22(17.3)        2(3.4)               2(9)              20(17.1)              NA              NA                  83(7.7)              18(12.9)          18(7.5)                                            NA
  Peripheral vascular disease(%)                       NA                                                   18(12.5)       NA             17(14.3)       22(17.3)        9(15.5)              1(5)              11(9.4)               NA              11(7.5)             101(9.4)             3(2.1)            22(9.2)                                            46(18)
  Arrhythmias(%)                                       NA                                                   34(23.6)       394(28.1)      25(21.0)       18(14.2)        19(32.8)             1(5)              51(43.6)              NA              NA                  170(15.6)            16(11.4)          NA                                                 NA
  Moderate‐to‐severe renal disease(%)                  NA                                                   20(13.9)       NA             NA             45(35.7)        19(32.8)             9(41)             NA                    29(27.1)        48(32.8)            156(14.5)            32(22.9)          NA                                                 66(25)
  Peptic ulcers(%)                                     NA                                                   NA             NA             NA             NA              7(12.1)              NA                NA                    NA              NA                  NA                   NA                NA                                                 NA
  Thyroid disease(%)                                   NA                                                   NA             NA             NA             NA              10(17.2)             NA                NA                    NA              NA                  NA                   NA                NA                                                 NA
  Anemia(%)                                            NA                                                   NA             NA             NA             NA              NA                   NA                NA                    NA              NA                  331(33.5)            NA                NA                                                 NA
  Severe anemia(%)                                     NA                                                   NA             NA             NA             NA              NA                   NA                NA                    NA              NA                  146(14.8)            NA                NA                                                 NA
  Chronic obstructive pulmonary disease(%)             NA                                                   36(25.0)       NA             31(26.1)       19(14.8)        NA                   NA                17(14.5)              NA              32(21.9)            NA                   NA                NA                                                 NA
  Heart failure(%)                                     NA                                                   34(23.6)       288(20.5)      26(21.9)       32(25.6)        NA                   4(18)             21(17.9)              NA              75(51.4)            73(6.8)              40(28.6)          NA                                                 NA
  Cancer disease(%)                                    NA                                                   NA             NA             NA             NA              NA                   NA                15(12.8)              4(3.7)          51(34.9)            93(8.7)              NA                NA                                                 NA
  Dementia(%)                                          NA                                                   NA             NA             NA             NA              NA                   NA                NA                    4(3.7)          NA                  37(3.4)              NA                NA                                                 NA
  Smoking(%)                                           NA                                                   35(32.4)       765(54.5)      91(76.5)       20(15.8)        8(13.8)              NA                23(19.7)              44 (41.9)       96(65.8)            282(31.2)            52(37.1)          92(38.3)                                           80(30)
  Family history (%)                                   NA                                                   14(18.9)       NA             11(17.7)       NA              24(41.4)             NA                NA                    NA              NA                  243(29.5)            NA                29(12.1)                                           NA
  Medicaments[a](#clc23230-note-0003){ref-type="fn"}                                                                                                                                                                                                                                                                                                                
  Aspirin (%)                                          NA                                                   NA             1041(74.2)     51(53.1)       NA              NA                   NA                72(64.9)              NA              86(66.7)            983(90.7)            64(45.7)          NA                                                 154(73)
  P2Y12 inhibitors (%)                                 NA                                                   NA             655(46.7)      13(13.5)       NA              NA                   NA                46(41.4)              NA              33(25.6)            786(72.6)            6(4.3)            NA                                                 72(34)
  GP IIb/IIIa antagonist (%)                           NA                                                   NA             NA             NA             NA              NA                   NA                NA                    NA              11(8.5)             34(3.2)              NA                NA                                                 NA
  Heparin (%)                                          NA                                                   NA             NA             NA             NA              NA                   NA                NA                    NA              NA                  801(74.0)            NA                NA                                                 NA
  Beta‐blocker (%)                                     NA                                                   NA             1146(81.7)     44(45.8)       NA              NA                   NA                86(77.5)              NA              88(68.2)            595(55.4)            81(57.8)          NA                                                 165(78)
  ACEI/ARB antagonist (%)                              NA                                                   NA             937(66.8)      38(39.6)       NA              NA                   NA                88(79.3)              NA              62(48.1)            566(52.4)            66(47.1)          NA                                                 NA
  Ca‐channel blocker (%)                               NA                                                   NA             NA             NA             NA              NA                   NA                NA                    NA              32(24.8)            161(15.1)            41(29.3)          NA                                                 NA
  Nitrate (%)                                          NA                                                   NA             NA             NA             NA              NA                   NA                NA                    NA              NA                  425(39.7)            NA                NA                                                 NA
  Aldosterone receptor antagonists(%)                  NA                                                   NA             NA             NA             NA              NA                   NA                22(19.8)              NA              NA                  NA                   6(4.3)            NA                                                 NA
  Diuretic (%)                                         NA                                                   NA             706(50.3)      NA             NA              NA                   NA                70(63.1)              NA              NA                  373(34.8)            46(32.8)          NA                                                 NA
  Statin (%)                                           NA                                                   NA             926(66.0)      38(39.6)       NA              NA                   NA                92(82.9)              NA              83(64.3)            698(64.8)            57(40.7)          NA                                                 153(72)
  Digoxin(%)                                           NA                                                   NA             81(5.8)        NA             NA              NA                   NA                NA                    NA              NA                  NA                   6(4.3)            NA                                                 NA
  Oral anticoagulant(%)                                NA                                                   NA             219(15.6)      10(10.4)       NA              NA                   NA                44(39.6)              NA              NA                  NA                   20(14.3)          NA                                                 NA
  Anti‐arrhythmic(s) (%)                               NA                                                   NA             NA             NA             NA              NA                   NA                NA                    NA              NA                  NA                   3(2.1)            NA                                                 NA
  Intervention                                                                                                                                                                                                                                                                                                                                                      
  Coronary angiography (%)                             NA                                                   31(21.5)       504(35.9)      28(25.5)       34(27)          NA                   1(5)              46(39.3)              NA              19(13.0)            660(60.5)            13(9.3)           58(24.2)                                           68(26)
  PCI (%)                                              NA                                                   NA             175(12.5)      4(3.4)         17(13.5)        NA                   0(0)              11(9.4)               NA              8(5.5)              557(51.1)            1(0.7)            7(2.9)                                             32(12)

Abbreviation IQR, interquartile range;PCI, percutaneous coronary intervention.

Referred to patients alive at discharge.

Stands for median (IQR).

To evaluate the quality of included studies, we applied the improved Newcastle‐Ottawa Quality Assessment Scale (NOS) for nonrandomized studies.[11](#clc23230-bib-0011){ref-type="ref"} All prospective or retrospective cohort studies received a rating of high (NOS ≥7) or acceptable quality (NOS ≥6) in this systematic review, respectively.

The baseline clinical characteristics and treatment of patients with T2MI are summarized in Table [1](#clc23230-tbl-0001){ref-type="table"}.[4](#clc23230-bib-0004){ref-type="ref"}, [12](#clc23230-bib-0012){ref-type="ref"}, [13](#clc23230-bib-0013){ref-type="ref"}, [14](#clc23230-bib-0014){ref-type="ref"}, [15](#clc23230-bib-0015){ref-type="ref"}, [16](#clc23230-bib-0016){ref-type="ref"}, [17](#clc23230-bib-0017){ref-type="ref"}, [18](#clc23230-bib-0018){ref-type="ref"}, [19](#clc23230-bib-0019){ref-type="ref"}, [20](#clc23230-bib-0020){ref-type="ref"}, [21](#clc23230-bib-0021){ref-type="ref"}, [22](#clc23230-bib-0022){ref-type="ref"}, [23](#clc23230-bib-0023){ref-type="ref"}, [24](#clc23230-bib-0024){ref-type="ref"} The mean age of patients with T2MI was over 60 years; most studies revealed that the percentage of male patients ranged from 52.8% to 98.6% in patients with T2MI, but the studies of Szymariski et al., Sandoval et al., and Arora et al. found percentages of female patients of 60.3%, 59%, and 51.9%, respectively.[17](#clc23230-bib-0017){ref-type="ref"}, [18](#clc23230-bib-0018){ref-type="ref"}, [24](#clc23230-bib-0024){ref-type="ref"} The ratio of patients with T2MI presenting with non‐ST segment elevation myocardial infarction (NSTEMI) ranged from 70.1% to 97.5% (mean value: 87.1%); all studies found that patients with T2MI often had previous relevant medical history, but EI‐Haddad et al. did not describe medical history findings.[12](#clc23230-bib-0012){ref-type="ref"} Only seven studies described the multiple medications used by patients with T2MI after discharge, which mainly included aspirin, P2Y12 inhibitors, beta blockers, angiotensin‐converting enzyme inhibitor (ACEI), angiotensin II receptor blocker (ARB), and statins. Detailed medication regimens are also described. Eleven studies showed 5% to 60.5% (mean value: 26.1%) of patients with T2MI were diagnosed by coronary angiography, and 10 studies showed that 0% to 51.1% (mean value: 11.1%) of patients with T2MI received percutaneous coronary intervention (PCI).

The triggers for T2MI are shown in Table [2](#clc23230-tbl-0002){ref-type="table"}. The common causes of T2MI were arrhythmia, anemia, hypertension, sepsis/infection, respiratory failure, hypotension, heart failure, and postoperative factors. Nine studies revealed the leading cause of T2MI was arrhythmia, especially tachyarrhythmia. On the contrary, Radovanovic et al. and Stein et al. found that the most common cause was anemia,[4](#clc23230-bib-0004){ref-type="ref"}, [16](#clc23230-bib-0016){ref-type="ref"} while EI‐Haddad et al., Szymariski et al., and Arora et al. revealed the most common triggers were postoperative factors, coronary artery spasm, and sepsis/infection, respectively.[12](#clc23230-bib-0012){ref-type="ref"}, [17](#clc23230-bib-0017){ref-type="ref"}, [24](#clc23230-bib-0024){ref-type="ref"}

###### 

Different triggers of T2MI in selected studies

                               Instigating factors                                                    
  --------------------- ------ --------------------- ----- ---- ----- ---- ---- ----- ---- ----- ---- -----
  EI‐Haddad H 2012      295    9                     9     NA   31    31   32   71    NA   10    82   29
  Saaby L 2013          144    46                    42    4    30    30   1    9     NA   NA    NA   13
  Baron T 2014          1403   331                   331   NA   186   19   30   246   NA   260   NA   184
  Saaby L 2014          119    48                    44    4    21    38   NA   14    NA   NA    NA   14
  Stein GY 2014         127    22                    NA    NA   39    NA   NA   30    NA   14    18   18
  Szymariski FM 2014    58     15                    NA    NA   11    NA   9    NA    NA   NA    NA   23
  Sandoval Y 2015       22     8                     8     NA   NA    NA   6    NA    8    NA    NA   NA
  Lopez‐Cuenca A 2016   117    43                    43    NA   6     NA   NA   NA    NA   18    NA   NA
  Landes U 2016         107    36                    36    NA   NA    NA   NA   NA    NA   NA    27   NA
  Smilowitz NR 2017     146    53                    43    10   29    25   29   43    20   NA    NA   NA
  Radovanovic D 2017    685    204                   204   NA   331   NA   NA   36    36   NA    51   NA
  Sandoval Y 2017       140    71                    66    5    11    57   59   NA    34   NA    NA   7
  Nestelberger T 2017   240    139                   123   16   7     3    64   NA    NA   NA    NA   NA
  Arora S 2018          264    16                    NA    NA   19    47   19   74    7    28    8    46

Figure [2](#clc23230-fig-0002){ref-type="fig"} shows the comparison between the single‐ and multiple‐trigger T2MI in six selected studies and shows that the proportion of single‐trigger T2MI was higher than that of multiple‐trigger T2MI, while Figure [3](#clc23230-fig-0003){ref-type="fig"} shows that 2‐trigger T2MI constituted the majority of multiple‐trigger cases.[15](#clc23230-bib-0015){ref-type="ref"}, [16](#clc23230-bib-0016){ref-type="ref"}

![Column chart showing the comparison between single‐trigger and multi‐trigger T2MI in selected studies](CLC-42-1019-g002){#clc23230-fig-0002}

![Doughnut chart showing the multi‐trigger T2MI frequencies in patients with T2MI. A, Saaby et al; B, Stein et al](CLC-42-1019-g003){#clc23230-fig-0003}

4. DISCUSSION {#clc23230-sec-0004}
=============

A key finding of this review is that the clinical characteristics of patients with T2MI, which were similar to those of found by Gupta et al.[25](#clc23230-bib-0025){ref-type="ref"} Patients with T2MI were older, more often men, more frequently presented with NSTEMI, and had a higher prevalence of cardiovascular risk factors or comorbidities, such as hypertension, smoking, dyslipidemia, diabetes, obesity, heart failure, impaired renal function, anemia, coronary artery disease, atrial fibrillation, cancer, peripheral artery disease, and chronic obstructive pulmonary disease. In this review, most selected studies revealed that the number of men with T2MI was higher than that of women, while a reduced number of studies found the opposite.[17](#clc23230-bib-0017){ref-type="ref"}, [18](#clc23230-bib-0018){ref-type="ref"}, [24](#clc23230-bib-0024){ref-type="ref"} For example, Gupta et al. described T2MI was more common in females compared with T1MI.[25](#clc23230-bib-0025){ref-type="ref"} Among the clinical characteristics of T2MI, we concluded that cardiovascular risk factors or comorbidities might be the most important causes of T2MI and affect the prognosis in these patients. The poor short‐ and long‐term prognosis is not entirely surprising since T2MI typically occurs among older patients with greater comorbidities and is identified in the context of hemodynamic instability.[26](#clc23230-bib-0026){ref-type="ref"} T2MI has a high mortality, and most deaths among patients with T2MI are due to noncardiovascular causes. Putot et al. revealed that T2MI was associated with a worse in‐hospital prognosis than T1MI resulting from non‐cardiovascular events.[27](#clc23230-bib-0027){ref-type="ref"} Smilowitz et al. showed that the rates of non‐cardiovascular deaths were 82.4%, 68.2%, and 64.4% in patients with T2MI during hospital admission, 30 days post‐discharge, and at intermediate‐term follow‐up, respectively.[21](#clc23230-bib-0021){ref-type="ref"} Lambrecht et al. showed T2MI led to a significantly higher long‐term mortality than T1MI, and noncardiovascular causes (57.4%) of death predominated in patients with T2MI, mainly including respiratory system diseases (20.6%), neoplasms (13.2%), and other noncardiovascular diseases (16.2%).[28](#clc23230-bib-0028){ref-type="ref"} Arora et al. found that 23 (50%) patients with T2MI died from infection or sepsis, which constitute noncardiovascular death causes.[24](#clc23230-bib-0024){ref-type="ref"} Few studies confirm that T2MI has worse outcomes independent of severe concomitant diseases. On the other hand, patients with T2MI were less likely to undergo coronary angiography (CAG) or PCI or to receive secondary preventive treatment than patients with T1MI. The impact of anti‐thrombotic and/or antiplatelet therapy, as well as the role of reperfusion in patients with T2MI due to mild atherosclerotic coronary stenosis might be beneficial or effective, but in patients without plaque rupture this benefit is uncertain and there might even be a detrimental effect or contraindication to treatment in many cases.[19](#clc23230-bib-0019){ref-type="ref"}, [29](#clc23230-bib-0029){ref-type="ref"} Otherwise, patients with T2MI often receive specific treatments for concomitant diseases, such as anticoagulants for atrial fibrillation or diuretics for heart failure. Regardless of the definition, we agree that the optimal medical therapy should be based on the cause of T2MI.

This review systematically evaluated T2MI triggers and listed the leading cause and other common causes, especially in single‐trigger cases; our findings also shed light on the underlying etiologies, which may help improve the decision regarding treatment options. In the TRACER trial, the most frequent potential provoking factor for T2MI was tachyarrhythmia (38.2%), which is consistent with our findings.[30](#clc23230-bib-0030){ref-type="ref"} A meta‐analysis also demonstrated that the most common associated arrhythmia was tachyarrhythmia, especially atrial fibrillation, in patients with T2MI.[25](#clc23230-bib-0025){ref-type="ref"} Most patients with T2MI died from noncardiovascular causes during long‐term follow‐up. However, few studies described the association between cardiovascular trigger and prognosis in patients with T2MI, which is crucial for clinicians. Therefore, opportunities exist to identify high cardiovascular risk patients and facilitate evidence‐based therapies geared toward improving their outcomes.[31](#clc23230-bib-0031){ref-type="ref"}

Distinguishing patients with T2MI from those with T1MI might be particularly challenging and requires a careful clinical assessment. It is crucial that the differentiation is made whether the myocardial injury is likely to be due to plaque rupture or to an imbalance between myocardial oxygen supply and demand, because the management of these two conditions is quite different. While the treatment of T1MI primarily includes antithrombotic therapy and/or revascularization, as clinically appropriate, the management of T2MI is more varied because several different mechanisms may be responsible for the pathological ischemic imbalance. Although visualization of a culprit lesion on angiography is often required to define a T1MI by clinicians and/or researchers, it may result in misclassification. Among patients with T2MI, in which the index event appears to be related to underlying undiagnosed coronary artery disease, CAG should be considered. Therefore, it should be routinely used to differentiate T1MI and T2MI, but not confirm the diagnosis of T2MI. The diagnosis of T2MI should be done by combining the detection of acute myocardial injury, clinical presentation of acute myocardial ischemia, and evidence of myocardial oxygen supply‐demand mismatch. Sandoval et al. stressed that using objective evidence of myocardial ischemia to diagnose T2MI might result in a more precise and specific disease definition.[32](#clc23230-bib-0032){ref-type="ref"} Moreover, establishing the trigger factors is essential for the diagnosis of T2MI.

To date, T2MI is a controversial matter in both clinical practice and research trials. There was no standardized clarification of the diagnostic criteria for T2MI. Although various suggestions have been made, these have not been widely accepted. Most importantly, there is an urgent need for evidence‐based diagnostic and therapeutic strategies, primarily randomized, controlled clinical trials.[19](#clc23230-bib-0019){ref-type="ref"}

There are several limitations to this systematic review. First, it is based on a relatively small number of selected patients. T2MI cases are not representative of the local population they were been derived from, and the study population is heterogeneous. The study period is narrow and might not be able to represent the whole spectrum of patients with T2MI adequately. In addition, selection bias may be present due to the heterogeneity of included patients due to the subjectivity of the diagnostic criteria for T2MI and to the different diagnostic methods used.[33](#clc23230-bib-0033){ref-type="ref"} Second, the objectives of individual studies are variable. This has potential consequences on the procedures used and on the reliability of how underlying conditions and their distribution among T2MI cases were established. Third, this review only includes retrospective and prospective cohort studies, but not prospective randomized controlled studies. Several selected studies have incomplete documentation for the key factors in this investigation. All individual studies lack information on how the underlying causes were established. Despite a rigorous statistical analysis, residual confounding and selection bias are likely to be present.

5. CONCLUSION {#clc23230-sec-0005}
=============

The leading trigger of T2MI was arrhythmia, especially tachyarrhythmia, and single‐trigger cases represented the majority of cases. Among multiple‐trigger cases of T2MI, two‐trigger cases are the most common. T2MI often occurs in older patients with cardiovascular risk factors or comorbidities. As for the triggering factors, non‐cardiovascular causes are closely related to the diagnosis and prognosis of T2MI. Furthermore, the optimal medical therapy should be decided based on the trigger of T2MI. Although recent data are promising, more prospective randomized controlled studies are necessary to verify the impact of different triggers on the diagnosis, treatment, and prognosis of T2MI.
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